Weed, Inc. (BUDZ): Total Liabilities
$1.25M
As of 2025-12-31
$1.44M
As of 2026-06-30
-5.2%
3-year compound annual growth
+5.9%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.25M | +30.1% | 2026-04-08, Balance as of period end |
| 2024-12-31 | $959.4K | +47.9% | 2026-04-08, Balance as of period end |
| 2023-12-31 | $648.8K | -55.7% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $1.46M | +9.1% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $1.34M | +43.2% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $937.3K | +24.5% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $753.0K | +190.3% | 2021-03-31, Balance as of period end |
| 2018-12-31 | $259.4K | -72.6% | 2020-03-30, Balance as of period end |
| 2017-12-31 | $948.1K | n/a | 2019-04-16, Balance as of period end |
| No annual figure between 2011-12-31 and 2017-12-31. | |||
| 2011-12-31 | $243.1K | +27.6% | 2012-04-16, Balance as of period end |
| 2010-12-31 | $190.6K | n/a | 2012-04-16, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Weed, Inc. (BUDZ) | 2025-12-31 | $1.25M | +30.1% |
| NRC Health (NRC) | 2025-12-31 | $120.89M | +19.4% |
| Incyte Corp (INCY) | 2025-12-31 | $1.79B | -10.3% |
| Icon PLC (ICLR) | 2025-12-31 | $7.08B | -1.6% |
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $3.92B | -2.4% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $31.02M | -6.6% |
| Cannabis Bioscience International Holdings, Inc. (CBIH) | 2025-05-31 | $1.20M | +5.2% |
| Iqvia Holdings Inc. (IQV) | 2025-12-31 | $23.31B | +11.9% |
| iSpecimen Inc. (ISPC) | 2025-12-31 | $6.44M | +6.7% |
Compare BUDZ, NRC, INCY, ICLR side by side · Screen every company in Services-Commercial Physical & Biological Research ↗